Abeona Therapeutics Inc SMA 50
What is the SMA 50 of Abeona Therapeutics Inc?
The SMA 50 of Abeona Therapeutics Inc is $5 +9.77%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with sma 50 similar to Abeona Therapeutics Inc
- Leverage Sha Etp 2070 has SMA 50 of €5 -6.76%
- Harbour Centre Development has SMA 50 of HKD$5 -1.76%
- Oil States International has SMA 50 of $5 -13.20%
- Hospital of China has SMA 50 of HKD$5 -26.00%
- Acco Brands has SMA 50 of $5 +2.31%
- Virtus Stone Harbor Emerging Markets Total Income Fund has SMA 50 of $5 -0.46%
- Abeona Therapeutics Inc has SMA 50 of $5 +9.77%
- Cathay Pacific Airways has SMA 50 of $5 -0.31%
- MicroPort Scientific has SMA 50 of HKD$5 -9.73%
- Sangamo Therapeutics has SMA 50 of €5 +0.06%
- PyroGenesis Canada has SMA 50 of $5 +99.72%
- United Carpets plc has SMA 50 of GBX5 -16,733.33%
- Fondul Proprietatea SA has SMA 50 of $5 -8.60%